Catalyst Pharmaceuticals (NASDAQ:CPRX) Lowered to “Hold” Rating by Robert W. Baird

Robert W. Baird cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a strong-buy rating to a hold rating in a research report released on Thursday morning,Zacks.com reports.

Several other brokerages have also recently issued reports on CPRX. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday. Finally, Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Three analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $31.15 on Thursday. The business has a fifty day moving average of $25.31 and a 200 day moving average of $23.93. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of 18.43, a price-to-earnings-growth ratio of 1.01 and a beta of 0.72.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. State Street Corp grew its stake in shares of Catalyst Pharmaceuticals by 7.8% during the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock worth $161,224,000 after purchasing an additional 502,235 shares during the period. Deerfield Management Company L.P. lifted its stake in shares of Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after purchasing an additional 2,095,291 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Catalyst Pharmaceuticals by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after buying an additional 433,318 shares in the last quarter. Fundsmith LLP grew its position in Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals News Summary

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion, or $31.50 per share in cash, which is above where the stock had been trading and typically supports a takeover premium. Closing is expected in the third quarter of 2026. Italy’s Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
• Positive Sentiment: Catalyst also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs, pushing any potential generic competition to January 2035 and resolving all pending FIRDAPSE patent disputes. That reduces legal overhang for the business. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: The company canceled its first-quarter 2026 conference call and webcast, which may have drawn attention but does not appear to be a major fundamental development on its own. Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• Negative Sentiment: Stephens downgraded Catalyst to Equal Weight from Overweight, which can weigh on sentiment even though the downgrade may be overshadowed by the acquisition bid. Stephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)
• Negative Sentiment: Law firms announced shareholder investigations into whether Catalyst is receiving a fair price in the Angelini transaction, creating a small litigation-related overhang. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).